Sarepta Therapeutics Inc (SRPT)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | PHARMACEUTICALS |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Douglas S. Ingram |
| Employees: | 840 |
| Web site: | sarepta.com |
|
215 FIRST STREET, SUITE 415, CAMBRIDGE, MA, 02142
617-274-4000
| |
-
Formally known as:
- AVI Biopharma, Inc
| Date | Ratio |
|---|---|
| 2012-07-12 | 1:6 |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio.
Please log in first to see chart